Luminescent diagnostics of skin defects in the near-infrared range

Abstract

Photodynamic therapy becomes a widely spread method due to cancer growth in the world. However, to detect tumors at early stages, it is necessary to carry out diagnostic measures in a timely manner. Our aim was to test the developed pharmaceutical composition, which can be used for external application in early fluorescent diagnostics even in the absence of visual changes, as well as for therapy effectiveness control. Pharmacokinetic studies on laboratory animals and volunteers were carried out. The results have shown that the dipotassium salt of Yb3+-dimethoxyhematoporphyrin IX, which is highly soluble in water and stable in storage, is a promising marker for earlier diagnostics of tumors and can be used in dermatology, dentistry, gynecology, cosmetology, ear, nose, and throat diseases, veterinary, and in other areas of medicine.